US4642291A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cell surface antigens of human astrocytoma
Assignee: Memorial Sloan Kettering Cancer Center
•
Filing: 1982-09-01
•
Granted: 1987-02-10
•
Expires: 2002-09-01
Abstract
Abstract Method of forming an antibody producing hybridoma cell line by fusing a myeloma cell line with splenocytes derived from BALB/c mice immunized with human astrocytoma tumor cells, the hybridoma cell line formed, and the monoclonal antibodies generated by said hybridoma cell line. A method of phenotyping astrocytoma tumor cells comprising determining the reaction of said cells to various monoclonal antibodies to astrocytoma tumor cells is also provided.
Inventors
- 👤 J. Gregory Cairncross
- 👤 M. Jules Mattes
- 👤 H. Richard Beresford
- 👤 Anthony P. Albino
- 👤 Alan N. Houghton
- 👤 Kenneth O. Lloyd
- 👤 Lloyd J. Old
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 10:17
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
104 words
Two or more monoclonal anbibodies capable of restricted and non-restricted binding to two or more human astrocytoma cell antigens and capable of subsetting malignant human astrocytoma cells into successive differentiation states wherein said restricted monoclonal antibody is selected from the group consisting of AJ 8, AJ225, A010, A050, A092 and A0122 and said non-restricted monoclonal antibody is selected from the group consisting of AJ2, AJ9, AJ10, AJ17, AJ60 and AJ425, and wherein said monoclonal antibody is capable of subsetting human astrocytomas into antibody binding classes selected from the group consisting of: AJ8 positive/A010 negative/GFA negative, AJ8 negative/A010 positive/GFA positive and AJ8 negative/A010 positive/GFA negative.
Claim 2
Dependent Claim
104 words
Two or more monoclonal anbibodies capable of restricted and non-restricted binding to two or more human astrocytoma cell antigens and capable of subsetting malignant human astrocytoma cells into successive differentiation states wherein said restricted monoclonal antibody is selected from the group consisting of AJ 8, AJ225, A010, A050, A092 and A0122 and said non-restricted monoclonal antibody is selected from the group consisting of AJ2, AJ9, AJ10, AJ17, AJ60 and AJ425, and wherein said monoclonal antibody is capable of subsetting human astrocytomas into antibody binding classes selected from the group consisting of: AJ8 positive/A010 negative/GFA negative, AJ8 negative/A010 positive/GFA positive and AJ8 negative/A010 positive/GFA negative.
Claim 3
Dependent Claim
17 words
Monoclonal antibody producing hybridoma cell lines characterized by the production of the monoclonal antibodies of claim 1.
Claim 4
Dependent Claim
14 words
Monoclonal antibodies of claim 1 comprising a panel for the diagnosis of human astrocytoma.
Claim 5
Dependent Claim
52 words
Method for differentiating between normal human astrocyte cells and abnormal human astrocytoma cells or differentiating between astrocytoma cells which comprises contacting a human astrocyte or astrocytoma cell specimen with at least two of the monoclonal antibodies of claim 1 and detecting one or more malignant astrocytoma cell antigens reacting with said antibody.
Claim 6
Dependent Claim
37 words
Method of phenotyping human astrocytoma cells which comprises contacting a human astrocytoma cell or tissue specimen with each of the monoclonal antibodies of claim 1, observing the antigen-antibody response, and determining the presence or absence of GFA.
Claim 7
Dependent Claim
28 words
Monoclonal antibody panel of claim 1 consisting of two or more of the monoclonal antibodies selected from the group consisting of AJ8, AJ225, A010, A050, A092 and A0122.
Claim 8
Dependent Claim
58 words
A test kit for differentiating human astrocytomas comprising monoclonal antibodies AJ8 and A010 in amounts sufficient to be capable of subsetting human astrocytomas into antibody binding classes, when used together with GFA testing reagents, wherein the astrocytoma classes are selected from the group consisting of AJ8 positive/A010 negative/GFA negative, AJ8 negative/A010 positive/GFA positive and AJ8 negative/A010 positive/GFA negative.
Claim 9
Dependent Claim
58 words
A test kit for differentiating human astrocytomas comprising monoclonal antibodies AJ8 and A010 in amounts sufficient to be capable of subsetting human astrocytomas into antibody binding classes, when used together with GFA testing reagents, wherein the astrocytoma classes are selected from the group consisting of AJ8 positive/A010 negative/GFA negative, AJ8 negative/A010 positive/GFA positive and AJ8 negative/A010 positive/GFA negative.
Claim 10
Dependent Claim
34 words
Method of subsetting human astrocytomas which comprises contacting a human astrocytoma specimen with monoclonal antibody AJ8 and A010 separately, observing an antigen-antibody reaction or lack thereof and determining the presence or absence of GFA.
Claim 11
Dependent Claim
34 words
Method of subsetting human astrocytomas which comprises contacting a human astrocytoma specimen with monoclonal antibody AJ8 and A010 separately, observing an antigen-antibody reaction or lack thereof and determining the presence or absence of GFA.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-02-09 | 1990-08-11 | 1991-02-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-02-09 | 1994-08-11 | 1995-02-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-02-09 | 1998-08-11 | 1999-02-10 | $7700.00 | Window Closed / Lapsed |